Table 2. Genomic regions with prognostic effect of copy number aberrations (CNA).
| Region ID | Chr | cytoBands | Mb | CNA frequency | Disease-free survival | Overall survival | Lung-cancer specific survival | Genes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loss | Gain | HR for loss* (95% CI) | HR for gain** (95% CI) | P | Q | HR for loss* (95% CI) | HR for gain** (95% CI) | P | Q | HR for loss* (95% CI) | HR for gain** (95% CI) | P | Q | ||||||||
| 142 | 7 | p12.3–p11.2 | 8.0E+0 | 0.7% | 17% | 0.51 (0.31–0.82) | 2.0 (1.2–3.2) | 0.005 | 0.142 | ||||||||||||
| 185 | 8 | p11.1–q11.1 | 4.0E+0 | 7.3% | 17.4% | 2.0 (1.2–3.1) | 0.51 (0.32–0.82) | 0.005 | 0.130 | ||||||||||||
| 211 | 9 | p21.3 | 3.0E−1 | 34.8% | 3.4% | 1.7 (1.3–2.3) | 0.57 (0.44–0.76) | <0.001 | 0.020 | 1.8 (1.4–2.5) | 0.55 (0.41–0.74) | <0.001 | 0.029 | 1.8 (1.4–2.4) | 0.55 (0.41–0.74) | <0.001 | 0.019 | ||||
| 212 | 9 | p21.3 | 6.0E−1 | 35.9% | 3.3% | 1.6 (1.2–2.0) | 0.64 (0.49–0.84) | 0.001 | 0.076 | 1.7 (1.3–2.2) | 0.59 (0.44–0.79) | <0.001 | 0.044 | 1.6 (1.2–2.1) | 0.62 (0.47–0.83) | 0.001 | 0.062 | ||||
| 213 | 9 | p21.3 | 6.0E−2 | 38.7% | 3.2% | 1.5 (1.2–1.9) | 0.67 (0.53–0.86) | 0.001 | 0.076 | 1.5 (1.2–2.0) | 0.66 (0.51–0.86) | 0.002 | 0.079 | 1.5 (1.2–2.0) | 0.65 (0.50–0.85) | 0.001 | 0.062 | ||||
| 214 | 9 | p21.3 | 3.0E−1 | 40.2% | 3.0% | 1.5 (1.2–1.9) | 0.66 (0.53–0.81) | <0.001 | 0.020 | 1.5 (1.2–1.9) | 0.67 (0.54–0.84) | <0.001 | 0.049 | 1.6 (1.2–2.0) | 0.64 (0.51–0.80) | <0.001 | 0.021 | CDKN2A, CDKN2B | |||
| 215 | 9 | p21.3 | 2.0E+0 | 36.3% | 3.3% | 1.6 (1.2–2.1) | 0.62 (0.48–0.81) | <0.001 | 0.034 | 1.7 (1.3–2.2) | 0.59 (0.45–0.79) | <0.001 | 0.044 | 1.7 (1.3–2.2) | 0.61 (0.46–0.80) | <0.001 | 0.029 | ||||
| 217 | 9 | p21.3 | 9.0E−3 | 35.0% | 3.9% | 1.7 (1.3–2.2) | 0.60 (0.46–0.79) | <0.001 | 0.026 | 1.5 (1.2–2.1) | 0.65 (0.48–0.87) | 0.004 | 0.084 | 1.7 (1.3–2.3) | 0.58 (0.44–0.78) | <0.001 | 0.026 | ||||
| 218 | 9 | p21.3 | 5.0E−1 | 32.8% | 4.5% | 1.6 (1.2–2.2) | 0.61 (0.45–0.82) | 0.001 | 0.076 | 1.7 (1.2–2.3) | 0.60 (0.43–0.83) | 0.002 | 0.079 | 1.7 (1.2–2.4) | 0.59 (0.42–0.82) | 0.002 | 0.064 | ||||
| 219 | 9 | p21.3–2 | 2.0E+0 | 30.5% | 4.6% | 1.8 (1.2–2.6) | 0.57 (0.39–0.82) | 0.003 | 0.106 | 1.8 (1.2–2.7) | 0.56 (0.37–0.83) | 0.004 | 0.084 | 1.9 (1.2–2.8) | 0.54 (0.36–0.80) | 0.002 | 0.085 | ||||
| 220 | 9 | p21.2 | 2.0E−2 | 30.1% | 4.8% | 1.6 (1.2–2.1) | 0.64 (0.47–0.86) | 0.004 | 0.11 | ||||||||||||
| 222 | 9 | p21.1 | 2.0E+0 | 27.8% | 5.2% | 1.9 (1.2–2.8) | 0.54 (0.36–0.81) | 0.003 | 0.084 | ||||||||||||
| 223 | 9 | p21.1 | 7.0E−1 | 26.0% | 6.4% | 1.8 (1.2–2.8) | 0.54 (0.36–0.82) | 0.003 | 0.084 | ||||||||||||
| 312 | 14 | q23.1 | 1.0E−1 | 8.5% | 8.9% | 2.2 (1.3–3.6) | 0.46 (0.28–0.76) | 0.002 | 0.079 | ||||||||||||
| 366 | 18 | q12.1 | 1.0E+0 | 10.8% | 8.6% | 1.9 (1.2–3.1) | 0.52 (0.32–0.82) | 0.005 | 0.105 | ||||||||||||
| 367 | 18 | q12.1 | 6.0E−1 | 10.9% | 7.1% | 2.0 (1.2–3.3) | 0.49 (0.30–0.80) | 0.005 | 0.092 | ||||||||||||
| 368 | 18 | q12.1 | 1.0E−3 | 12.1% | 6.6% | 1.6 (1.2–2.3) | 0.61 (0.44–0.85) | 0.004 | 0.119 | 1.7 (1.2–2.5) | 0.58 (0.41–0.82) | 0.002 | 0.079 | 1.7 (1.2–2.4) | 0.59 (0.42–0.85) | 0.004 | 0.11 | ||||
| 376 | 19 | p13.3 | 1.0E+0 | 10.7% | 0.4% | 2.4 (1.3–4.3) | 0.42 (0.23–0.77) | 0.005 | 0.142 | FSTL3, STK11 | |||||||||||
| 378 | 19 | p13.3–2 | 8.0E+0 | 9.2% | 0.3% | 2.6 (1.4–4.8) | 0.38 (0.21–0.72) | 0.003 | 0.106 | 2.9 (1.5–5.6) | 0.34 (0.18–0.66) | 0.001 | 0.078 | 3.4 (1.7–6.6) | 0.29 (0.15–0.58) | <0.001 | 0.029 | MLLT1, SH3GL1, TCF3, VAV1 | |||
| 379 | 19 | p13.2 | 3.0E−3 | 10.3% | 0.9% | 2.2 (1.3–3.8) | 0.45 (0.26–0.76) | 0.003 | 0.106 | 2.3 (1.3–4.2) | 0.43 (0.24–0.77) | 0.004 | 0.092 | 2.6 (1.4–4.6) | 0.39 (0.22–0.69) | 0.001 | 0.062 | ||||
| 380 | 19 | p13.2–p12 | 1.0E+1 | 8.0% | 2.2% | 2.7 (1.4–5.1) | 0.38 (0.20–0.73) | 0.004 | 0.084 | LYL1, RAB8A, ELL, CDKN2D | |||||||||||
| 383 | 19 | p12–p11 | 4.0E+0 | 8.0% | 2.5% | 2.4 (1.4–4.2) | 0.42 (0.24–0.74) | 0.003 | 0.106 | 2.7 (1.5–5.0) | 0.36 (0.2–0.66) | <0.001 | 0.066 | 2.5 (1.3–4.5) | 0.41 (0.22–0.75) | 0.004 | 0.11 | ||||
The univariate hazard ratio (HR) for loss shows the relative risk of a patient with a 2-fold lower CN, for example one copy as compared to two copies. The HR for gain shows the relative risk of a patient with a 2-fold higher CN, for example four copies as compared to two copies. Of note, HR for gain is 1/HR for loss. CI, confidence interval; Chr, chromosome. *, hazard ratio for a 2-fold lower copy number; **, hazard ratio for a 2-fold higher copy number.